China Market Research Company | China Market Entry | China Market Analysis

Life Sciences

Home >> Views >> Life Sciences

Guangzhou Baiyunshan Pharma is to construct 2 new manufacturing bases with RMB 700mln

Source：CCMR Data：2013-12-31

Guangzhou Baiyunshan Pharmaceutical Co. of Guangzhou Pharma plans to invest RMB 700mln in building 2 new manufacturing bases to produce the renowed Wanglaoji herbal tea.

The two new bases locate in Guangdong Province and Hunan Province, respectively. After completion, the 2 new bases will be able to extract, produce and bottle 40 tonnes herbal tea syrup and 20mln standard cases of Wanglaoji Herbal Tea.

·Chinese Healthcare Spending

·Monthly Output of Chinese Patent Medicine, Jan.2011-Oct.2012

·Fairwood (HKG:0052) repurchases 41K shares

·Interchina (HKG:0202) places shares for $359M

·Venturepharm (HKG:8225) to halt trading for results release

·Wuyi Pharma (HKG:1889) 2011 net profit RMB57M, down 46%; div HK$0.008

·Lijun (HKG:2005) sinks to red, 2011 NL $41M; div 2 ct

·Healthy Living

·BMS Banks on Innovative Drugs to Double China Sales

·Genetic Technologies executes agreement with Eurofins STA

·Takeda announces establishment of development center in China

·Roche supports animal conservation research

·Fudan-Zhangjiang (HKG:8231) Sees 2011 Net Profit Up Sharply

·IDT acquires 1st BASE oligonucleotide business

·BioDiem licenses LAIV technology to Changchun BCHT

Copyright © 2012-2020 CCMR | China Ceidea Market Research Co., LTD Inc. All rights reserved.
Add：Room 406 Huide Building No 102 Hao Xian Road Yuexiu District Guangzhou Tel：+86-020-28931413 +86 13503051005
BINWEB